{
    "clinical_study": {
        "@rank": "45084", 
        "arm_group": [
            {
                "arm_group_label": "Patients of palmer arsenical keratosis", 
                "arm_group_type": "Experimental", 
                "description": "Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks"
            }, 
            {
                "arm_group_label": "Arsenic exposed controls", 
                "arm_group_type": "Active Comparator", 
                "description": "Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks"
            }, 
            {
                "arm_group_label": "Heathy volunteers", 
                "arm_group_type": "Active Comparator", 
                "description": "Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The role of anaerobic bacteria in the pathogenesis of palmer arsenical keratosis is not\n      known. This can be evaluated by administering probiotics. Thirty patients from an arsenic\n      affected area will be provided two probiotics capsules per day orally  for 12 weeks and\n      stool samples will be collected for qualitative and quantitative analysis of anaerobic\n      bacteria. Similar number of arsenic exposed controls and healthy volunteers from the same\n      area will be included with similar protocol for comparison. Like aerobic bacteria, anaerobic\n      bacteria may be modulated by probiotics in arsenicosis patients."
        }, 
        "brief_title": "Modulation of Anaerobic Gut Bacteria of Arsenicosis Patients by Probiotics", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Arsenic Poisoning", 
        "condition_browse": {
            "mesh_term": [
                "Poisoning", 
                "Arsenic Poisoning"
            ]
        }, 
        "detailed_description": {
            "textblock": "Recent study done by our laboratory shows that there are reduction in the number of E. coli\n      in the gut of patients with arsenical keratosis which is increase by the administration of\n      probiotics (manuscript is preparing). However, E.coli contribute only about 0.1% of the\n      total gut bacteria. It is not known whether anaerobic bacteria play an important role in the\n      pathogenesis of arsenical keratosis. This can be evaluated by administering probiotics.\n      Thirty patients of moderate arsenical palmer keratosis from an arsenic affected area will be\n      recruited on the basis of inclusion and exclusion criteria. They will be provided two\n      probiotics capsules per day orally  for 12 weeks. Water sample will be collected before\n      starting the study for confirming the diagnosis. Stool samples will be collected twice\n      (before and after completion of the study) for qualitative and quantitative analysis of\n      anaerobic bacteria. Similar number of arsenic exposed controls (30) and healthy volunteers\n      (30) from the same area will be included in this study and they will be provided probiotics\n      capsules with similar dosage and duration. Like aerobic bacteria, anaerobic bacteria may be\n      modulated by probiotics in arsenicosis patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (Patients):\n\n          -  history of taking arsenic contaminated water (>50 ppb) for more than 6 months\n\n          -  patients having moderate arsenical keratosis  present on palm of the hand\n\n          -  patients those voluntarily agree to participate\n\n        Inclusion Criteria (Arsenic exposed controls):\n\n          -  family member of the patient\n\n          -  drinking arsenic contaminated water from the same source as patient\n\n          -  those voluntarily agreed to participate\n\n          -  no sign/symptoms of palmer keratosis\n\n        Inclusion Criteria (Healthy volunteers):\n\n          -  drinking arsenic safe water <50 ppb)\n\n          -  those voluntarily agreed to participate\n\n        Exclusion Criteria:\n\n          -  pregnancy\n\n          -  lactating mother\n\n          -  patient receiving treatment of arsenicosis\n\n          -  any other chronic disease like tuberculosis, diabetes, asthma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726426", 
            "org_study_id": "BSMMU-001-CT"
        }, 
        "intervention": {
            "arm_group_label": [
                "Patients of palmer arsenical keratosis", 
                "Arsenic exposed controls", 
                "Heathy volunteers"
            ], 
            "description": "Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks", 
            "intervention_name": "Probiotic", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Chronic arsenic poisoning", 
            "Palmer arsenical keratosis"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dhaka", 
                    "country": "Bangladesh", 
                    "zip": "1000"
                }, 
                "name": "Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University"
            }
        }, 
        "location_countries": {
            "country": "Bangladesh"
        }, 
        "number_of_arms": "3", 
        "official_title": "Modulation of Anaerobic Gut Bacteria in Palmer Arsenical Keratosis Patients by Supplementation With Probiotics", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Bangladesh: Ethical Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of pathogenic anaerobic bacteria in the stool of patients will be decrease in comparison to arsenic exposed controls and volunteers after 12 weeks supplementation with probiotics.", 
            "measure": "Number of pathogenic anaerobic bacteria in stool", 
            "safety_issue": "No", 
            "time_frame": "0 weeks (baseline), 12 weeks (end)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726426"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", 
            "investigator_full_name": "Prof. Mir Misbahuddin", 
            "investigator_title": "Prof. and Chairman, Department of Pharmacology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Arsenic level in the stool of patients will be increased in comparison to arsenic exposed controls and healthy volunteers. Arsenic level will be estimated using Atomic Fluorescence spectrometer.", 
                "measure": "Arsenic level in stool", 
                "safety_issue": "No", 
                "time_frame": "0 week (baseline), 12 weeks (end)"
            }, 
            {
                "description": "There will be improvement of moderate palmer keratosis following supplementation with probiotics.", 
                "measure": "Changes in palmer keratosis following supplementation", 
                "safety_issue": "No", 
                "time_frame": "0 week (baseline), 12 weeks (end)"
            }
        ], 
        "source": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}